Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Revision: v3.5.4 replaces the previous v3.5.3 label, signaling a backend or UI update unrelated to study details.
    Difference
    0.0%
    Check dated 2026-05-15T02:14:54.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The Taiwan location entry was updated from Taoyuan District, Taiwan, 33305 to Taoyuan, Taiwan, 33305, replacing the district designation with the city name while preserving the postal code.
    Difference
    0.0%
    Check dated 2026-05-07T22:10:27.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The page shows an updated Revision: v3.5.3, replacing v3.5.2, reflecting a software/version update applied to the page.
    Difference
    0.0%
    Check dated 2026-04-30T16:31:08.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2 on the page. No user-facing content changes are indicated.
    Difference
    0.0%
    Check dated 2026-04-16T10:10:41.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The site version was updated from v3.4.3 to v3.5.0; no visible content changes were introduced.
    Difference
    0.0%
    Check dated 2026-03-25T20:40:19.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Hepatocellular Carcinoma is now listed under Conditions and a Resources section with the Genetic and Rare Diseases Information Center has been added.
    Difference
    0.1%
    Check dated 2026-03-18T14:53:32.000Z thumbnail image

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.